Founded in Cambridge in 1998, biotech firm Abcam made a name for itself producing high-quality, validated antibodies for ...

Bispecific antibodies seem to be all the rage at the minute. Their ability to deliver targeted therapeutics to patients with a two-in-one approach by simultaneously binding to two different antigens ...

The founder of Abcam, Jonathan Milner, transformed the way scientists access antibodies. Under his leadership as chief executive officer (CEO) until 2014, Abcam grew into a multinational entity with a ...